share_log

Heart Test Laboratories | 10-Q: Q3 2024 Earnings Report

Heart Test Laboratories | 10-Q: Q3 2024 Earnings Report

Heart Test Laboratories | 10-Q：2024财年三季报
美股sec公告 ·  03/14 16:14
Moomoo AI 已提取核心信息
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
Heart Test Laboratories, a medical technology company, has not provided specific financial performance metrics such as revenue, operating profit, net profit, or diluted earnings per share in its latest quarterly report. However, the company has disclosed stock-based compensation for stock options, which increased from $149,153 in the nine months ended January 31, 2023, to $326,578 in the same period in 2024. Deferred tax assets have also been reported, with a net operating loss carryforwards of approximately $52 million as of January 31, 2024, up from $46 million the previous year. The company has entered into significant business development agreements, including a multi-year collaboration with Rutgers University and multiple definitive license agreements with Mount Sinai for AI cardiovascular algorithms. Heart Test Laboratories plans to submit a 510(k) FDA submission for its MyoVista device and is aiming for clearance within the 2024 calendar year. The company has also received patent allowances in various regions and has entered into financial agreements to support its operations, including an Equity Distribution Agreement with Maxim Group LLC.
医疗技术公司Heart Test Laboratories在其最新的季度报告中未提供具体的财务表现指标，如营业收入、营业利润、净利润或股份瑕疵收益率等。然而，该公司已披露股票期权的股票补偿，由2023年1月31日结束的9个月中的$149,153增加到2024年同期的$326,578。推迟的税款资产也已报告，2024年1月31日的净营业亏损仍达5200万美元，较上年增长了4600万美元。该公司已经与多个机构签订了重大的业务发展协议，包括与罗格斯大学的多年合作以及与Mount Sinai签订的AI心血管算法多项明确授权协议。Heart Test Laboratories计划为MyoVista设备提交510(k) FDA申请，并力争在2024年日历年内获得清关。该公司还在各个地区获得了专利许可并签订了支持其业务的金融协议，包括与Maxim Group LLC的股权分销协议。
医疗技术公司Heart Test Laboratories在其最新的季度报告中未提供具体的财务表现指标，如营业收入、营业利润、净利润或股份瑕疵收益率等。然而，该公司已披露股票期权的股票补偿，由2023年1月31日结束的9个月中的$149,153增加到2024年同期的$326,578。推迟的税款资产也已报告，2024年1月31日的净营业亏损仍达5200万美元，较上年增长了4600万美元。该公司已经与多个机构签订了重大的业务发展协议，包括与罗格斯大学的多年合作以及与Mount Sinai签订的AI心血管算法多项明确授权协议。Heart Test Laboratories计划为MyoVista设备提交510(k) FDA申请，并力争在2024年日历年内获得清关。该公司还在各个地区获得了专利许可并签订了支持其业务的金融协议，包括与Maxim Group LLC的股权分销协议。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息